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Abstract
With half of the world’s population at risk for malaria infection and with drug resistance on
the rise, the search for mutation-resistant therapies has intensified. We report here a ther-
apy for Plasmodium falciparum malaria that acts by inhibiting the phosphorylation of eryth-
rocyte membrane band 3 by an erythrocyte tyrosine kinase. Because tyrosine
phosphorylation of band 3 causes a destabilization of the erythrocyte membrane required
for parasite egress, inhibition of the erythrocyte tyrosine kinase leads to parasite entrap-
ment and termination of the infection. Moreover, because one of the kinase inhibitors to
demonstrate antimalarial activity is imatinib, i.e. an FDA-approved drug authorized for use
in children, translation of the therapy into the clinic will be facilitated. At a time when drug
resistant strains of P. falciparum are emerging, a strategy that targets a host enzyme that
cannot be mutated by the parasite should constitute a therapeutic mechanism that will
retard evolution of resistance.
Introduction
The inaugural meeting of theWorld Health Organization in 1948 designatedmalaria as one of
six consensus global health priorities [1]. However, despite remarkable victories over smallpox
(1979) and polio (1988), malaria still remains a major health problem, with nearly half of the
world’s population at risk of contracting the disease and nearly 600,000 deaths per year arising
from the parasitemia [1]. According to theWHO, children under the age of 5 are especially
vulnerable, with one child dying of the disease everyminute [2]. The absence of an effective
vaccine [3] and the continuing emergence of resistance to existing antimalarials [4, 5]
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foreshadow a possible global health crisis that can only be addressed by introduction of muta-
tion-resistant therapies [6, 7].
Five species of protozoans belonging to the genus Plasmodium cause malaria, but the most
lethal of the species is Plasmodium falciparum. During the intra-erythrocyticphase of its life-
cycle, the parasite matures through ring, trophozoite, and schizont stages that are characterized
by increasing tyrosine phosphorylation of the erythrocytemembrane protein, band 3 [8–10].
Because this phosphorylation has been shown to dramatically weaken the membrane, leading
to erythrocytevesiculation and eventual red cell rupture [11, 12], the hypothesis has arisen that
P. falciparum promotes tyrosine phosphorylation of band 3 in order to facilitate its egress from
the erythrocyte, thereby enabling its propagation. In exploring this hypothesis, we learned that
others have discovered that the P. falciparum genome surprisingly encodes no classical tyrosine
kinase [13, 14], suggesting that any tyrosine phosphorylation of band 3 must either be per-
formed by an erythrocyte tyrosine kinase or an unrelated P. falciparum kinase with the ability
to phosphorylate tyrosines [15, 16]. This observation in turn lead us to believe that an inhibitor
of the erythrocyte tyrosine kinase could disrupt the P. falciparum life cycle by preventing its
egress from the red cell. To test this hypothesis, we screened inhibitors of the five known eryth-
rocyte tyrosine kinases (i.e. syk [11, 17], lyn [18], hck [19], fgr [19], and src [20]) for their anti-
malarial activity. In this paper, we report that imatinib, a well-tolerated tyrosine kinase inhibi-
tor that is FDA-approved for use in children, prevents parasite-induced tyrosine phosphoryla-
tion of band 3 and terminates P. falciparum parasitemia in vitro by blocking parasite egress at
clinically relevant concentrations.
Results
Tyrosine Kinase Inhibitor Treatment
The major erythrocytemembrane protein, band 3 (AE1, SLC4A1, anion transporter) forms the
predominant bridge connecting the red cell membrane to its spectrin/actincytoskeleton via an
association with ankyrin [21–24]. In previous studies we have shown that tyrosine phosphory-
lation of band 3 causes dissociation of ankyrin [11, 25], leading to rupture of this membrane-
to-cytoskeleton bridge and the consequent membrane destabilization, vesiculation and hemo-
lysis [11, 12, 26, 27]. Curiously, P. falciparum infection of human erythrocytes (RBCs) pro-
motes a gradual but significant increase in band 3 tyrosine phosphorylation [8] despite the
absence of any tyrosine kinases encoded in the parasite genome [13, 14]. Because this gradual
increase in band 3 tyrosine phosphorylation coincides with the rise in membrane vesiculation
and eventual erythrocyte rupture [8], this observation raises the possibility that an erythrocyte
tyrosine kinasemight be co-opted by the parasite to promote erythrocytemembrane destabili-
zation and facilitate merozoite egress. The purpose of the studies describedbelow was to inves-
tigate this hypothesis.
To begin to assess which erythrocyte tyrosine kinasemight be activated by P. falciparum, we
examined the abilities of inhibitors of the five known erythrocyte tyrosine kinases to prevent
parasite propagation in vitro. As shown in Table 1 and S2 Fig, untreated parasite cultures and
cultures treated with dasatinib, i.e. a broad spectrum tyrosine kinase inhibitor (TKI) that sup-
presses the activities of bcr-abl, src, lck, yes, fyn, lyn, hck, c-kit, EPHA2, and PDGFRβ displayed
an unabated increase in parasitemia, demonstrating that dasatinib can neither prevent parasite
egress nor block P. falciparum reinvasion/proliferation in fresh human RBCs. In contrast, ima-
tinib, PRT062607, gefitinib, R406, bafetinib, nilotinib, and PP-121 all showed measurable anti-
malarial activity, with the latter three displaying higher potencies than the former four (S1–S3
Figs). However, because imatinib i) was previously shown to inhibit the major erythrocyte tyro-
sine kinase (syk) that phosphorylates band 3 [28], ii) was the only inhibitor tested that is FDA-
Imatinib Prevents Plasmodium falciparum Egress
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approved for use in children [29, 30], and iii) can be taken daily in perpetuity by cancer patients
with little associated toxicity [31, 32], this tyrosine kinase inhibitor was selected for further
investigation.
Effect of imatinib on malaria parasite maturation and propagation in vitro
To obtain an accurate assessment of the anti-malaria potency of imatinib in vitro, synchronized
P. falciparum cultures were treated with increasing doses of imatinib and parasitemia was
assessed 60 h after drug administration (i.e. 72 h after initiation of the first cycle). As shown in
Fig 1A, imatinib effectively suppressed parasitemia in culture, with essentially complete inhibi-
tion achieved at ~5 μM. To verify that this suppression was stable and not a temporary inter-
ruption of parasite growth, synchronized cultures were treated with a single dose of imatinib
and monitored through 5 consecutive infective life cycles. As seen in Fig 1B, untreated cultures
showed a stepwise increase in parasitemia through all five life cycles, i.e. demonstrating that
the parasites were capable of proliferating in the erythrocyte cultures throughout the 10-day
experiment. In contrast, concentrations of imatinib that were previously found to eliminate all
parasitemia by the end of the parasite’s first life cycle (Fig 1B) were also found to prevent para-
sitemia recurrencewhen cultures were monitored for an additional four life cycles. Although
Table 1. Identification of erythrocyte tyrosine kinase inhibitors that treat Plasmodium falciparum malaria in vitro.
Drug Name Kinase(s)
Inhibited
Present in RBC? Drug Status (FDA Approval) Approved for Pediatric
Use?
IC50 (μM)*
Bafetinib Bcr-Abl No Phase I/II trials completed No 1.34a,b
Lyn Yes
Dasatinib Bcr-Abl No Sprycel® approved for leukemia in adults only. No >10b
Src, Lck, Yes, Fyn No
Lyn, Hck Yes
c-kit No
EPHA2 No
PDGFRβ No
R406 Syk Yes Phase II trial underway for ITP No >1, <10b
Gefitinib EGFR No Iressa® approved for NSCLC cancer in adults only. No >1, <10b
Lyn Yes
Imatinib Bcr-Abl No Gleevec® approved for CML and GIST adults and
children.
Yes 3.03a,b
PDGFRβ No
c-kit No
SCF No
Syk, Lyn Yes
Nilotinib Bcr-Abl No Tasigna® approved for CML in adults only. No <1b
Lyn Yes
PP-121 Abl No Removed from Pfizer drug development pipeline No 0.83a,b
PDGFRβ No
VEGFR2 No
Hck, Src Yes
PRT062607 Syk, Lyn, Hck, Fgr Yes Phase I trial completed No 3.29a,b
*Approximate IC50 values for each drug were determined by treating ring stage cultures of P. falciparum with different concentrations of each drug and
quantitating residual parasitemia 60 h later.
a P. falciparum Palo Alto strain was used for the experiments
b P. falciparum Dd2 strain was used for the experiments
doi:10.1371/journal.pone.0164895.t001
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the cultures treated with 4 μM imatinib appeared to recover after the 132 hour time point, we
suspect this delayed rise in parasitemia derives from the proliferation of surviving parasites not
killed during initial exposure to this suboptimal concentration (4 μM) of imatinib rather than
emergence of drug resistance. At higher imatinib concentrations the data suggest that drug
exposure can completely suppress parasite proliferation (Fig 1B and S1 Table).
Tyrosine phosphorylation of Band 3 in infected RBCs
We next determinedwhether imatinib might cause elimination of the parasitemia by inhibiting
the parasite-induced tyrosine phosphorylation of band 3, as hypothesized in the proposed
mechanism. As shown in Fig 2, anti-phosphotyrosine immunoblots of membranes derived
from uninfected RBCs displayed no detectable tyrosine phosphorylation of band 3, consistent
with previous observations by multiple authors [11, 33–35]. In contrast, membranes from ring
and trophozoite stage infected RBCs showed significant tyrosine phosphorylation of band 3
Fig 1. Effect of imatinib on survival of P. falciparum malaria in human erythrocyte cultures. (A) Effect
of different concentrations of imatinib on the survival of P. falciparum in human erythrocyte cultures.
Synchronized ring stage (12hpi) P. falciparum (Palo Alto strain) cultures at 0.5% parasitemia were treated
with the indicated concentrations of imatinib, and after 60h incubation, % parasitemia was quantitated by flow
cytometry (see Methods). Results were obtained from three independent experiments, with each
concentration examined in triplicate in each experiment. (B) Effect of a single treatment of imatinib on the
long term survival of P. falciparum in human erythrocyte cultures. Synchronized ring stage parasites were
treated 12h post-infection (time 0) with increasing concentrations of imatinib and % parasitemia was
evaluated every 12 hours, as described above. To assure the continuous availability of nutrients for any
proliferating parasites and to prevent loss of parasitized RBCs during media replacement, 2/3 of the media
was replaced with fresh media every 24h beginning at the 72-hour time point. Results were obtained with
each concentration examined in triplicate.
doi:10.1371/journal.pone.0164895.g001
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that appeared to increase, as previously noted [9, 12], as maturation of the parasite proceeded
(membranes from schizont stage RBCs were very difficult to isolate and consequently not
examined). Importantly, membranes from infected RBCs treated with a low concentration of
imatinib (1 μM) displayed reduced tyrosine phosphorylation of band 3 and this suppression of
band 3 tyrosine phosphorylation was almost quantitative by 5 μM imatinib; i.e. the concentra-
tion that eliminated all parasitemia. These data demonstrate that imatinib inhibits the tyrosine
phosphorylation of band 3 over the same concentration range where it inhibits parasitemia.
Inhibition of parasite egress from infected RBCs
The proposedmechanism of imatinib action further posits that inhibition of band 3 tyrosine
phosphorylation should prevent the membrane destabilization required for merozoite egress at
the end of the parasite’s life cycle. To test this step in the mechanism, we next monitored both
the development and eventual escape of parasites from untreated and imatinib-treated syn-
chronized P. falciparum cultures. As shown in the light micrographs of Fig 3A, healthy para-
sites from untreated cultures displayed the normal 48 h life cycle, proceeding from RBC
infection through ring, trophozoite and schizont stages of development to merozoite egress
and reinvasion within the expected time span (see images at 12, 36 and 52 h post infection). In
contrast, 5 μM imatinib-treated cultures displayed an interruption in development, with early
schizont-like parasites prominent at the 52 h time point when untreated cultures were begin-
ning their next life cycle. Moreover, many infected erythrocyteswere found to contain either
dead or dying parasites. At the 72 h time point, the 5 μM imatinib-treated cultures were still
dominated by either merozoite-like parasites entrapped within infected RBCs or pyknotic
Fig 2. Effect of imatinib on tyrosine phosphorylation of band 3 in P. falciparum infected
erythrocytes. Membranes were isolated from uninfected control erythrocytes (C) or P. falciparum-infected
erythrocytes treated at the ring (R) or trophozoite (T) stage with the indicated concentrations of imatinib.
Isolated membranes were separated by SDS-PAGE and transferred to nitrocellulose prior to western blotting
with an anti-phosphotyrosine antibody. The tyrosine phosphorylated band at 100kDa is band 3, as
demonstrated by mass spectrometry analysis of phosphopeptides [12]. Anti-actin staining of the same blots
is presented as gel loading control.
doi:10.1371/journal.pone.0164895.g002
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parasites displaying condensedDNA. By the beginning of the third life cycle (i.e. 96 h time
point), a few merozoite-like structures still remained in the treated samples, but most of the
infected cells contained disintegrating parasites with condensedDNA.
When the concentration of imatinib was increased to 10 μM, the trend of parasite entrap-
ment followed by disintegration was still observed, however, additional indications of growth
arrest and interruption of parasite maturation preceded parasite entrapment, suggesting that
this higher dose was more generally toxic. Indeed, all of the parasitized cells appeared pyknotic
by the 96 h time point, and few if any infected cells displayed signs of normal maturation at
any time point. These data suggest that lower doses of imatinib may terminate parasitemia by
Fig 3. Effect of imatinib treatment on P. falciparum maturation and egress. Synchronized ring stage parasites (12 hours after parasite invasion)
were either left untreated (top row) or treated with 5 μM (middle row) or 10 μM (bottom row) imatinib, and parasite morphology was assessed on blood
smears by light microscopy at 12, 24, 36, 42, 44, 46, 48, 50, 52, 72, 96 hours after invasion using a Nikon Eclipse CI-L microscope, Plan Fluor 100X oil
objective, Numerical Aperture 1.3 at room temperature equipped with a Nikon DS-Fi2 digital camera and NIS-Elements Basic Research acquisition
software. (A) Representative images at the indicated time points are shown, focusing on morphology of individual infected cells to enable easier
comparison. Note that at the 52 h time point, expected ring stage parasites are only seen in untreated cultures. (B) Quantitative analysis of 0 or 5μM
imatinib treated malaria infected RBCs at 42 hpi.
doi:10.1371/journal.pone.0164895.g003
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prevention of parasite egress, whereas higher doses likely induce parasite death by additional
unrelated mechanisms. A quantitative analysis of the fraction of infected RBCs at each stage of
parasite development following treatment with either 0 or 5 μM imatinib is shown in Fig 3B.
Importantly, at 42h post infection, when 28% of the untreated parasitized RBCs had egressed
and progressed to the ring stage of their second life cycle, none of the infected RBCs treated
with imatinib had progressed to this stage. Since analysis at other time points show a similar
failure of imatinib-treated cultures to enter their second life cycle, these data suggest that expo-
sure to imatinib inhibits progression of the parasites through their normal life cycle.
Stage Specific Sensitivity
Patients with symptomatic malaria experience severe fever roughly every 48 h, demonstrating
that the parasite’s life cycle is moderately synchronized in vivo [36]. Not surprisingly, artemisi-
nin, the first line of treatment for malaria in virtually all parts of the world, also displays a life
cycle dependence in its inhibition of parasite propagation [37, 38], with potency being greatest
when administered early in the parasite’s life cycle. Given the continuous increase in tyrosine
phosphorylation of band 3 in infected RBCs, the question naturally arose whether imatinib
might similarly need to be present early in the parasite’s life cycle to prevent merozoite egress.
To address this question, synchronized cultures of infected erythrocyteswere treated with ima-
tinib at different stages of their life cycle and monitored for egress and re-invasion of unin-
fected erythrocytes.As shown in Fig 4, the antimalarial activity of imatinib was most effective
when present at the beginning of the parasite’s life cycle, with imatinib potency gradually
decreasing as the parasite matured from its ring (100% suppression) to trophozoite (88% sup-
pression) to schizont (41% suppression) stage (see also S4 Fig). Since the phosphorylation-
Fig 4. Sensitivity of P. falciparum cultures to imatinib at different stages of the parasite’s life cycle.
Imatinib (8 μM) was added to synchronized P. falciparum (Dd2 strain) cultures at different stages of their life
cycle (i.e., ring stage ~7hpi, late ring stage ~14 hpi, trophozoite stage ~21 hpi, late trophozoite stage ~28 hpi,
and schizont stage ~36 hpi). Parasitemia was measured after the untreated parasites had progressed 24 h
into their second infective cycle. The absence of detectable parasitemia is reported in the plot as 100%
suppression. Note that imatinib must be present by late ring stage to achieve quantitative suppression of the
parasitemia.
doi:10.1371/journal.pone.0164895.g004
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induced weakening of the erythrocytemembrane is roughly proportional to the extent of band
3 tyrosine phosphorylation, the reduced potency of imatinib in later stage parasitized cells may
derive from the fact that band 3 has already been substantially phosphorylated at these later
stages of parasite development.
Analysis of Imatinib Activity against Clinical Isolates of P. falciparum
Infected Blood from Uganda
Since the majority of malaria infections are found in Sub-Saharan Africa [2], ex vivo studies to
assess the sensitivities of fresh field isolates of P. falciparum malaria infected blood samples to
imatinib were performed in Mbale, Uganda. As seen in Fig 5A, imatinib suppressed the parasi-
temia in these samples with an average IC50 of 1.37 μM (range 0.47–3.02 μM; n = 20). Surpris-
ingly, these data suggest that imatinib has greater anti-malarial activity against random field
Fig 5. Ex vivo drug susceptibility of fresh P. falciparum clinical isolates in Uganda to imatinib treatment. Fresh
blood samples from malaria patients were obtained with written informed consent and analyzed for their sensitivities to
imatinib as described in Methods. (A) The parasitemia of each sample was determined as a function of imatinib
concentration by qPCR analysis of extracted parasite DNA. Percent inhibition of parasitemia is plotted as a function of
imatinib concentration. (B) Parasite morphology was assessed by microscopic evaluation of thin blood smears stained
with fresh 10% Giemsa. Light micrographs of cultures were acquired using a Nikon Elipse CI-L microscope, Plan Fluor
100X oil objective, Numerical Aperture 1.3 at room temperature equipped with a Nikon DS-Fi2 digital camera and
NIS-Elements Basic Research acquisition software. Representative images at the indicated imatinib concentrations are
shown.
doi:10.1371/journal.pone.0164895.g005
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isolates of P. falciparum than laboratory-adapted strains of the same parasite (~5 μM; see
Fig 1). As shown in Fig 5B, all field isolates treated with 5 μM imatinib appeared pyknotic, with
shrunken parasites containing condensed nuclei (Fig 5B); i.e. similar to the laboratory-adapted
strains treated with 10 μM. These data raise the possibility that imatinib might constitute an
effective treatment for P. falciparum malaria at clinically acceptable concentrations of imatinib.
To further explore whether imatinib might serve as an effective antimalarial at concentra-
tions known to be nontoxic in humans, an analysis of the pharmacokinetics of imatinib at an
intermediate well-tolerated dose (600 mg) in cancer patients was required. Le Coutre et al. [39]
report that imatinib has a clearance half-time of 17h, an average Cmax of ~7 μM, and average
Cmin of ~2.5 μM in chronic myelogenous leukemia patients. Based on the complete inhibition
of parasitemia seen in both laboratory-adapted strains and random field isolates at 5 μM (Figs
1 and 5), one might speculate that some therapeutic benefit should be seen at this same dose in
malaria patients. More importantly, further scrutiny of the literature reveals that the major
imatinib metabolite in humans, N-desmethyl imatinib (CGP74588), is present in patient
plasma at a steady state level of ~1.4 μM [39]. BecauseN-desmethyl imatinib differs from the
parent drug by only a single methyl group, we next decided to explore whether it might simi-
larly exhibit anti-malarial activity. As shown in Fig 6A, N-desmethyl imatinib displays the
same anti-malaria activity as imatinib (Fig 6B IC50 = ~3.60 μM (see also S5 Fig)), suggesting
that it should probably contribute additively to suppression of the parasitemia in vivo. Taken
together, these results argue that the total concentration of pharmacologically active imatinib
in the serumof cancer patients should be sufficient to suppress the parasitemia in malaria
patients [39–41].
Discussion
Since the 2nd century BCE, all malaria therapies have targeted malaria-encodedprocesses that
are critical to parasite survival. Artemisinin, originally obtained by chewing the plant, Artemi-
sia annua, is thought to function by promoting oxidative stress and inhibiting hemozoin for-
mation within the infected red cell [42]. Quinine, found in the bark of the cinchona tree,
accumulates in the Plasmodium food vacuole and inhibits the formation of hemozoin among
other mechanisms [43, 44]. Synthetic quinine substitutes such as chloroquine, piperaquine,
and mefloquine have subsequently been introduced to offset the resistance that has emerged to
each preceding quinine congener [45], and several promising new therapies have been
designed to inhibit the P. falciparum cation ATPase (PfATP4), P. falciparum protein kinase G
(PfPKG), and P. falciparum phosphatidylinositol-3 kinase (PfPI3K) in the parasite [7, 46–49].
The obvious limitation of each of these approaches is that they target enzymes/processes
encoded in the parasite genome, allowing the parasite to explore resistance mechanisms via
constitutive mutagenesis. With many infected individuals containing>50,000,000 parasites/ml
blood, the probability of selecting a resistant mutant would seem high, especially given the ten-
dency of patients in remote regions to refrain from taking their full 3-day dosing regimen in
order to save the remaining pills for a subsequent bout with the disease [50]. These observa-
tions all argue that complete eradication of malaria may require a pharmaceutical that can tar-
get a host enzyme that cannot be mutated by the parasite [36].
In this article, we describe a novel antimalarial agent that blocks parasitemia by inhibiting a
process encoded in the host cell’s genome. As we have shown elsewhere, phosphorylation of
band 3 on tyrosines 8 and 21 is catalyzed by syk tyrosine kinase [51], leading to a major reorga-
nization of the RBCmembrane that induces release of glyceraldehyde 3-phosphate dehydroge-
nase, lactate dehydrogenase, phosphofructokinase, pyruvate kinase, aldolase and
deoxyhemoglobin from band 3 [52, 53]. More importantly, this phosphorylation also causes
Imatinib Prevents Plasmodium falciparum Egress
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displacement of ankyrin from band 3, severing the major bridge connecting the RBCmem-
brane to its structurally stabilizing cytoskeleton. The natural consequence of this membrane
reorganization in uninfected red cells is membrane weakening, bilayer vesiculation, and eryth-
rocyte hemolysis [11, 12, 26, 27]. The steady increase in tyrosine phosphorylation of band 3 in
parasitized erythrocytesundoubtedly leads to a similar membrane weakening, contributing to
the observedmembrane crenations and vesiculation seen in later stage infected red cells, and
ultimately to the successful egress of the parasite from the destabilized cell.
To inhibit this process, we treated the malaria infected cultures with imatinib, a tyrosine
kinase inhibitor that has known activity against syk [28]. The result of this treatment was pre-
vention of parasite egress. Although it cannot be ruled out that a P. falciparum encoded dual-
specificity kinasemight be capable of catalyzing the tyrosine phosphorylation of band 3, or that
imatinib might inhibit this kinase or some other parasite protein and thereby block parasite-
mia, the likelihood that such an unknown target constitutes the site of action of imatinib seems
remote, especially since the crystal structure of imatinib bound to syk shows a very high degree
Fig 6. Effect of the primary imatinib metabolite in humans, N-desmethyl imatinib, on inhibition of P.
falciparum parasitemia. P. falciparum strain Palo Alto cultures were treated during ring stage (0.5%
parasitemia) with increasing concentrations of (A) imatinib or N-desmethyl imatinib, and % parasitemia of
infected cultures was determined by flow cytometry every 24 hours after treatment to monitor parasite
replication. Note, open markers inhibited all parasitemia. (B) To create a dose response curve, cultures were
treated with concentrations of N-desmethyl imatinib, and the % inhibition of parasitemia was determined by
flow cytometry after a 60 h incubation.
doi:10.1371/journal.pone.0164895.g006
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of structural complementarity and the remarkable specificity of imatinib for a very limited
number of tyrosine kinases constitutes its source of notoriety [15, 16].
It is important to emphasize that the malaria parasite engages actively in erythrocytemem-
brane remodeling from the moment that it enters the red cell. Thus, novel malaria-encoded
proteins are repeatedly inserted into the host cytoskeleton and plasma membrane [54, 55],
while normal erythrocytemembrane proteins continually undergo parasite-induced phosphor-
ylation and proteolysis [56, 57]. Althoughmany of these modificationsmay have evolved to
render the erythrocytemore hospitable to parasite maturation, some of the changes have
undoubtedly emerged to weaken the red cell membrane and facilitate parasite egress at the end
of its life cycle [58, 59]. It will be interesting to determine whether inhibition of any of these
other parasite-encoded egress processes might synergize with inhibition of the band 3 tyrosine
phosphorylation in preventing progression of the parasite through its life cycle.
It is important to note that previous work from prominent labs has provided additional
motivation for seeking a malaria therapy that targets an erythrocyte-mediatedprocess. Thus,
Doerig and colleagues [60] have shown that inhibition of an erythrocyteMEK1 kinase using
allosteric inhibitors has parasiticidal effects on P. falciparum, both in red cells and in hepato-
cytes in vitro. Millholland and coworkers [57] have similarly found that activation of host pro-
tein kinase C is responsible for initiating a signaling cascade leading to proteolysis of the host
protein adducin, thus cleaving the second of the two major bridges (other than the ankyrin
bridge) that anchors the red cell membrane to its underlying cytoskeleton; i.e. further weaken-
ing the erythrocytemembrane. Along the same lines, this activation of protein kinase C or
casein kinase is also found to lead to phosphorylation of protein 4.1, causing disruption of the
spectrin-actin interaction and thereby contributing to the aforementioned membrane destabili-
zation [61, 62]. In a similar manner, Murphy et al. [63] have demonstrated that P. falciparum
co-opts an erythrocyteGs protein to activate signaling pathways required for intra-erythrocytic
parasite growth and invasion. Finally, Brizuela et al. [64] have reported that the parasite utilizes
a red cell antioxidant protein, peroxiredoxin 2, to compensate for its lack of catalase and inabil-
ity to rapidly detoxify hydrogen peroxide.When considered together, these observations sug-
gest that a wide variety of erythrocytepathways can potentially be targeted to develop a more
mutation resistant therapy for malaria.
In conclusion, we suggest that imatinib constitutes an excellent candidate for clinical evalua-
tion as an anti-malaria therapy for several reasons: i) it is FDA approved for use in both adults
and children, ii) it is generally non-toxic and can be taken daily in perpetuity, iii) well tolerated
concentrations demonstrating complete antimalarial activity can be achieved in patient’s
plasma, iv) imatinib has been well studied in nearly all human populations, and iv) imatinib’s
mechanism of action renders development of resistance mutations unlikely. With the focus of
the malaria field on the design of mutation-resistant drug cocktails that might collectively
enable eradication of parasitemia with a single pill, the contribution of a drug like imatinib
could prove valuable.
Materials and Methods
Parasites and Compounds
The Plasmodium falciparum strains used in these studies, Dd2 (MRA-156) and FUP Palo Alto
(MRA -915), were obtained fromMalaria Research and Reference Reagent Resource Center
(MR4). The protein tyrosine kinase inhibitors bafetinib, PP121, R406, PRT062607, dasatinib,
and nilotinib were purchased from Selleck Chemicals. Imatinib mesylate and N-desmethyl
imatinib were from AlsaChim.
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P. falciparum Culture and Synchronization
Fresh bloodwas collected from healthy adult volunteers into acid-citrate-dextrose (ACD) glass
vacutainer tubes (BD Biosciences) and prepared as previously described [11]. Written
informed consent was collected prior to blood donation. This study was approved by the Pur-
due University Institutional ReviewBoard and conducted in accordance with GoodClinical
Practice guidelines and the Declaration of Helsinki. Briefly, RBCs were separated from plasma
and leukocytes by three washings in wash media (RPMI 1640 (Invitrogen) media containing
2mM glutamine, 25mMHEPES, 20mM glucose, 27μg/mL hypoxanthine and 32μg/mL of gen-
tamicin (Sigma) (pH 7.2)). P. falciparum strains Palo Alto and Dd2 were then cultured at 1–5%
hematocrit, as previously describedbut with minor modifications [65]. Parasites were main-
tained under a 1% O2, 5% CO2, and 94% N2 atmosphere in complete media (wash media sup-
plemented with 0.5% Albumax II (Gibco)). Parasites were synchronized by isolating late stage
parasites on a Percoll density gradient (Sigma), washing 3x to remove the Percoll, and adding
the schizont stage parasitized cells to fresh RBC cultures. After 4 h incubation to allow for re-
invasion of fresh RBCs, cultures were treated with aqueous 5% sorbitol for 5 min at room tem-
perature to lyse any residual late stage parasitized cells, preserving primarily ring stage parasites
and uninfected RBCs [66, 67]. After allowing the synchronized parasites to mature and rein-
vade fresh RBCs, therapeutic studies with the listed pharmacological agents at the desired time
in hours post-invasion (hpi). To assess parasitemia and infected cell morphology, thin smears
were prepared, labeled with Diff-Quick stain (Siemens), and examined by light microscopy.
Drug Susceptibility Assays of Cultured Parasites
Synchronous ring stage P. falciparum Palo Alto or Dd2 strain infected erythrocyteswere
treated with the above tyrosine kinase inhibitors at 2% hematocrit and 0.5–2% parasitemia. All
inhibitors were solubilized in anhydrous DMSO at a 10mM stock concentration and serially
diluted in anhydrous DMSO prior to addition to malaria cultures. Untreated cultures were run
in parallel with the same final concentration of DMSO as the drug treated cultures. Parasitemia
was measured by flow cytometry at the desired time points and thin smears were prepared for
evaluation of parasite integrity and morphology by light microscopy (see below).
Analysis of Parasite Number and Morphology by Flow Cytometry and
Light Microscopy
Malaria infected erythrocyte cultures were stained with SYBR Green I DNA stain (1:10,000
final concentration (Invitrogen); excitation wavelength, 488nm) to quantitate residual percent
parasitemia using a BectonDickinson FACSCalibur flow cytometer according to well defined
procedures [68, 69]. Briefly, after 20-min incubation of the treated cultures in SYBR Green at
room temperature, the cells were washed 3X in PBS-glucose [PBS containing 5mM glucose
(pH 7.4)] and analyzed by flow cytometry. SYBR Green positive cells were assumed to be
infected cells, since all nonerythroid cells were previously removed during erythrocytewash-
ings and Percoll gradients. For each sample, 200,000 events were acquired using FL-1 channel
and analyzed using FlowJo software (Tree Star Inc.). Blood smears from each sample were also
prepared, fixed with methanol, stained in fresh 3.5% Giemsa modified stain solution (Fluka,
Sigma) for 10 minutes, and then assessed by light microscopy to evaluate parasite morphology
and integrity.
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Analysis of Band 3 Tyrosine Phosphorylation at Different Stages of
Malaria Maturation
P. falciparum-infected cells at 20% parasitemia and the desired stage of parasite maturation
were incubated for 24h in the presence of different concentrations of imatinib (0, 1 and 5μM)
and then lysed at 0°C in hemolysis buffer (5 mmol/L sodium phosphate, 1 mmol/L EDTA, pH
8.0) containing protease and phosphatase inhibitor cocktails (Sigma- Aldrich, St. Louis,MO,
USA). Erythrocytemembranes were prepared according to standard procedures [70] and
stored at -20°C until analysis. Isolated membranes were then solubilized in Laemmli Buffer
and loaded on to 8% polyacrylamide gels for SDS-PAGE. Proteins were transferred to nitrocel-
lulose membranes, probed with mouse anti-phosphotyrosine antibody ((Santa Cruz Biotech-
nology) diluted 1:1000, and visualizedwith anti-mouse secondary antibody conjugated to
IR800CW fluorescent dye (Li-COR-USA). Detectionwas performed using a 700–800 nm laser
scanner (Odissey, Licor, USA).
Ex vivo Sensitivity Testing of Clinical Isolates and quantification of
parasite DNA by qPCR
Blood samples were acquired with written informed consent from P. falciparum-infected
patients at theMbale Regional Referral Hospital, Mbale, Uganda, following approval from the
hospital’s IRB and from the Uganda National Council for Science and Technology. Research was
conducted according to the principles expressed in the Declaration of Helsinki. Infected erythro-
cytes were isolated by three washings in wash medium and resuspended at 2% hct in wash media
supplemented with 10% heat-inactivated human serum. Infected cultures were added to culture
plates pre-dosed with DMSO, dihydroartemisinin, or imatinib concentrations in triplicate and
maintained under a reduced oxygen atmosphere at 37°C. After a 50 h incubation, 10 μl of the
infected blood cell suspension were spotted onto filter paper in triplicate and dried at room tem-
perature for 20 minutes or stored at -20°C until use.Malaria parasite DNA was extracted accord-
ing to standard procedures [71] and DNA amplification was performed using primers and
probes for the 18S rRNA gene of P. falciparum as previously describedwith modifications [72].
Briefly parasite DNA was amplified in reaction buffer (1.5 mMMgCl2, 0.2 mM deoxynucleoside
triphosphate, 300 nM of each desired primer, 100 nM of the Taqman probe and 1U of Platinum
Taq polymerase (Life technologies, CA, U.S.A)). Amplification and detection of purified parasite
DNA were performedusing CFX96 Touch™ Real-Time PCRDetection System (Biorad) using
the following program: 95°C for 3 min, followed by 45 cycles at 95°C for 15 min and 60°C for 45
min. Samples were run in duplicate. Percent parasitemia was estimated using a standard curve
obtained from serial dilutions of P. falciparum DNA in cultures with known parasitemia using
CFXManager™ Software 3.1 (Biorad). The 50% inhibitory concentrations (IC50) were calculated
by nonlinear regression analysis using ICEstimator software 1.2 [73] and by counting percent
parasitemia in thin blood smears stained with 10% fresh Giemsa.
Supporting Information
S1 Fig. Effect of the tyrosine kinase inhibitors on inhibition of P. falciparum parasitemia.
Synchronous P. falciparum strain Palo Alto cultures were treated during ring stage (0.5% para-
sitemia) with increasing concentrations of bafetinib, PP-121, imatinib, PRT062607. After 60 h
incubation, % parasitemia of infected cultures was determined by flow cytometry. Results were
obtained with each concentration examined in triplicate. Error bars are within the size of the
point marker.
(TIF)
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S2 Fig. Time course effect on parasitemia of P. falciparum cultures treated with tyrosine
kinase inhibitors. Synchronous P. falciparum strain Palo Alto cultures were treated during
ring stage (0.5% parasitemia) with increasing concentrations of bafetinib, dasatinib, imatinib,
nilotinib, PP-121, PRT062607. Infected cultures were analyzed every 24 hours to determine%
parasitemia by flow cytometry. Results were obtained with each concentration examined in
triplicate.
(TIF)
S3 Fig. Time course effect on parasitemia of P. falciparum cultures treated with tyrosine
kinase inhibitors. Synchronous P. falciparum strain Dd2 cultures were treated during the late
ring stage (2% parasitemia) with increasing concentrations of bafetinib, dasatinib, R406, gefiti-
nib, imatinib, nilotinib, PP-121, PRT062607. Infected cultures were analyzed every 11–24
hours to determine% parasitemia by flow cytometry. Results were obtained with each concen-
tration examined in triplicate.
(TIF)
S4 Fig. Time course of % parasitemia in the multiple developmental stages cultured with 0
or 8 μM of imatinib. Imatinib (8 μM) was added to synchronized P. falciparum (Dd2 strain)
cultures at different stages of their life cycle, ring stage ~7hpi, late ring stage ~14hpi, trophozo-
ite stage ~21 hpi, late trophozoite stage ~28hpi, and schizont stage ~36hpi. Parasitemia was
measured by flow cytometry every 11 hours after treatment until the untreated parasites had
progressed 24 h into their second infective cycle. Results were obtained with each concentra-
tion examined in triplicate.
(TIF)
S5 Fig. Time course comparison of % parasitemia in imatinib and N-desmethyl imatinib
treated cultures. Synchronized ring stage (12hpi) P. falciparum (Palo Alto strain) cultures at
0.75% parasitemia were treated with the indicated concentrations N-desmethyl imatinib. After
60 h incubation, % parasitemia of infected cultures was determined by flow cytometry. Results
were obtained with each concentration examined in triplicate.
(TIF)
S1 Table. Effect of different concentrations of imatinib on parasite growth rate during the
first 12h of each life cycle.Conditions are as shown in Fig 1B. The percent parasite growth per
hour was calculated from the percent increase in parasitemia over the first 12h of each life
cycle.
(TIF)
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